Clinical Trial

ToFAcitinib in Early Active Axial SpondyloarThritis:

Study acronym: FASTLANE
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase IV, multicentre, randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of tofacitinib versus placebo (on a background of an NSAID) over 16 weeks of treatment and 4 weeks of safety follow-up in subjects with early active axSpA and inadequate response to at least one NSAID, with objective signs of inflammation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-29.
Status change: Not Yet Recruiting → Recruiting 2024-11-22
Trial Details
NCT Number NCT06112665
Lead Sponsor Charite University, Berlin, Germany
Collaborators: Pfizer
Conditions Axial Spondyloarthritis
Enrollment 104 participants
Start Date 2023-11-10
Primary Completion 2025-03 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2024-11-26